On the stock market since 2016, it operates in the world of health and science. It has 74 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
There is $411.6M in the vault; even if every debt were paid off, $411.6M would remain.
A loss of $183.8M against $0 in annual sales.
This stock swings about 2.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, MNMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MNMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.